Crossbeta gains new ceo and funding

Dutch biotech to advance technology in several therapeutic areas

Crossbeta Biosciences, based in Utrecht in The Netherlands has appointed Guus Scheefhals as chief executive.

Scheefhals has joined the biotech firm from Avantium, where he held several managerial positions, most recently as chief operating officer of the pharma business unit. Prior to Avantium, he held commercial positions at DSM Biologics, Analytico and NPBI, which is now part of Fresenius.

Scheefhals replaces Johan Renes, who steps down after being with the company from the start and for the past two years as part-time ceo.

Crossbeta has recently won funding of €2m, which will be used to advance the firm’s technology in several therapeutic areas and to establish a stronger position for co-development programmes and commercialisation partnerships.

You may also like

Research & Development

Probiodrug and Crossbeta Biosciences enter into a partnership in the field of Alzheimer’s disease biomarkers

Licensing and supply agreement is based on Crossbeta’s proprietary technology and supports Probiodrug’s biomarker development activities
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing

Abzena named a leader in Frost & Sullivan ADC CDMO radar report

Recognition highlights integrated capabilities, proprietary technology and expertise in antibody-drug conjugates
Design & Build

Entries closed: what’s next for the Cleanroom Technology Awards?

With entries now closed, attention turns to the next phase of the awards programme
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities

The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Subscribe now